Novartis Ag (NVS) Cash from Discontinued Operations (2014 - 2023)
Novartis Ag recorded quarterly Cash from Discontinued Operations of 164000000.0 in Q4 2023, up 121.62% quarter-over-quarter from 74000000.0 in Q3 2023, and down 52.19% year-over-year from 343000000.0 in Q4 2022.
Novartis Ag's Cash from Discontinued Operations history runs 6 years deep, the most recent figure standing at 164000000.0 for Q4 2023.
- In Q4 2023, Cash from Discontinued Operations fell 52.19% year-over-year to 164000000.0; the TTM figure through Dec 2023 stood at 402000000.0 (down 49.05% YoY), while the FY2023 annual figure was 238000000.0, down 80.12% from the prior year.
- Cash from Discontinued Operations came in at 164000000.0 for Q4 2023 at Novartis Ag, up from 74000000.0 in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of 499000000.0 in Q2 2019 to a low of 59000000.0 in Q2 2023.
- A 3-year average of 221000000.0 and a median of 134500000.0 in 2023 frame the typical range for Cash from Discontinued Operations.
- Across the five-year window, Cash from Discontinued Operations gained 16.05% in 2019 and slumped 83.41% in 2023, its largest moves.
- Novartis Ag's Cash from Discontinued Operations stood at 499000000.0 in 2019, then slumped by 31.26% to 343000000.0 in 2022, then tumbled by 52.19% to 164000000.0 in 2023.
- According to Business Quant data, Cash from Discontinued Operations over the past three periods registered 164000000.0, 74000000.0, and 59000000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 164.00 Mn |
| Dec 31, 2023 | 164.00 Mn |
| Sep 30, 2023 | 74.00 Mn |
| Sep 30, 2023 | 74.00 Mn |
| Jun 30, 2023 | 59.00 Mn |
| Jun 30, 2023 | 59.00 Mn |
| Mar 31, 2023 | 105.00 Mn |
| Mar 31, 2023 | 105.00 Mn |
| Dec 31, 2022 | 343.00 Mn |
| Dec 31, 2022 | 343.00 Mn |
| Sep 30, 2022 | 446.00 Mn |
| Sep 30, 2022 | 446.00 Mn |
| Jun 30, 2019 | 499.00 Mn |
| Jun 30, 2019 | 499.00 Mn |
| Mar 31, 2019 | 78.00 Mn |
| Mar 31, 2019 | 78.00 Mn |
| Dec 31, 2018 | 330.00 Mn |
| Dec 31, 2018 | 330.00 Mn |
| Sep 30, 2018 | 330.00 Mn |
| Sep 30, 2018 | 330.00 Mn |
| Jun 30, 2018 | 430.00 Mn |
| Jun 30, 2018 | 430.00 Mn |
| Mar 31, 2018 | 133.00 Mn |
| Mar 31, 2018 | 133.00 Mn |
| Dec 31, 2015 | 60.00 Mn |
| Dec 31, 2015 | 60.00 Mn |
| Sep 30, 2015 | -11.00 Mn |
| Sep 30, 2015 | -11.00 Mn |
| Jun 30, 2015 | -45.00 |
| Jun 30, 2015 | -45.00 |
| Mar 31, 2015 | -192.00 |
| Mar 31, 2015 | -192.00 |
| Dec 31, 2014 | 482.00 |
| Dec 31, 2014 | 482.00 |
| Sep 30, 2014 | 92.00 |
| Sep 30, 2014 | 92.00 |
| Jun 30, 2014 | -237.00 |
| Jun 30, 2014 | -237.00 |
| Mar 31, 2014 | -337.00 |
| Mar 31, 2014 | -337.00 |